Mike Bentivegna is currently Vice President, Commercial Development and Lifecycle Innovation, Zoetis Inc. He leads a group responsible for collaborating with R&D and the Commercial organization in establishing species innovation strategies, driving value in Zoetis’ R&D portfolio, and preparing new products for launch. Mike is a twenty-nine year veteran of Pfizer/Zoetis. He joined Animal Health in late 2010 as head of U.S. Companion Animal Marketing, where he served for five years, contributing to the business units success and elevating the skill set of its marketers. Zoetis was spun off from Pfizer in an IPO in 2013.
Mike previously spent thirteen years in Pfizer Human Health Marketing in senior marketing positions on major brands and therapeutic areas like Zyrtec, Zyvox, Spiriva, Eliquis, Pain and Inflammation (Celebrex), Cardiovascular (Lipitor/Caduet) in both U.S. Marketing and Global Commercial Development positions. Prior to human health, Mike spent his first ten years in Pfizer’s OTC division working on all of Pfizer’s leading OTC medicines and was the named the first global team leader for the division, responsible for the Eye Care TA and global strategy for the Visine franchise.
Mike is graduate of Fairfield University with a BS in Marketing and where he was elected Student Government President his senior year. He holds an MBA from the Sawyer School of Management at Suffolk University, where he received a full tuition graduate assistantship.
Mikes’ volunteer and support activities include Wakeman Boys and Girls Club, Operation Hope and Fairfield University where he was a past member of the Alumni Board of Directors and is currently is a mentor to ten Creative Life Sophomore Residential College students. He has been a member of the President’s Circle for over twenty years.
Mike lives in Southport, Connecticut with his wife Wendy and feline family members Ritz and Pippin. He has two adult children, Kevin and Brittney.
Elise Brownell, PhD. has spent the last 35 years in the bio/pharmaceutical arena where she has played key roles in Discovery, Development and Opportunity Assessment to drive innovation.
After completing her doctorate at Yale University, Elise’s career started at SUNY Stony Brook where she made discoveries relating to genetic evolution in the great apes. She continued her interest in comparative molecular biology during her tenure at Frederick Cancer Research Facility and expanded her facility with molecular genetics while in various functions at Bayer Healthcare. She played a pivotal role in directing discovery research in the areas of asthma, allergy, and immunology and continued her dedication to innovation by managing extramural collaborations for Bayer’s Biotechnology unit. Her efforts were widely recognized by promotion to Director, Project Management, where she led global cross-functional teams to bring several of Bayer’s biopharmaceuticals from bench to clinic. Her award-winning performance at Bayer was followed by becoming a member of the founding team of a venture-backed spin out (Aerovance, Inc), where she became head of project management. During her tenure as Senior Director, Aerovance garnered over $ 60 MUSD, completed six clinical trials in 3.5 years, and built a right-sized matrixed organization.
In 2008, she co-founded ZephyrBiotech, LLC, a consulting practice that provides project leadership, management and planning to entrepreneurial life science companies, especially those that are early-stage, venture-backed entities. Her experience within the investment community has been strengthened by her tenure with The Angels’ Forum (2012-2014), where she was responsible for managing all incoming deal flow and presentation preparation.
Currently, Dr. Brownell serves as Executive Vice President of Operations and Project Management at Amarantus Bioscience Holdings, Inc. where she oversees all development programs across a diverse therapeutics portfolio.
Most importantly, she is a highly regarded mentor/advisor for entrepreneurial programs conducted through Astia, UC Berkeley BPlan, and the NCI/SBIR Investor Forum.
Elise received her MS, MPhil and Ph.D. from Yale University, and her B.S. from Allegheny College. She is particularly proud of her Preparatory Diploma from Eastman School of Music in piano.
Anita Burrell is a dynamic, passionate and infectiously enthusiastic consultant focused on improving patient outcomes through pharmaceutical innovation. She is also an adjunct assistant professor at Rutgers University and a regular speaker in the industry on health economics, market access, and mHealth.
Anita has 23 years of leadership experience in the pharmaceutical industry in a wide variety of roles and geographies. As the Global Project Lead for Aubagio, the oral MS therapy from Genzyme, she was able to bring Aubagio to market over eight months ahead of schedule becoming the second oral therapy to market in the USA and EU. Aubagio is the fastest growing MS product in the US and the #1 product in the Genzyme/Sanofi portfolio with revenue of €1.3B in 2016.
As a consultant, Anita has helped companies to:
Anita holds a BA (Hons) in Economics from the University of Stirling, an M.A. in Economics from Dalhousie University, Nova Scotia, Canada, and a Masters in Business Administration from Kingston University, Surrey UK. She speaks French at an advanced level.
For more insight, visit https://www.linkedin.com/in/anitaburrell.
Ms. Cirillo joined Churchill Pharmaceuticals in 2016 and is responsible for all marketing aspects for their portfolio of cancer products. Churchill is a venture funded pharmaceutical company utilizing proprietary technology to improve the bioavailability and clinical aspects of oral cancer products.
Prior to Churchill, Sharlene was Head of Global Market Access for the oncology portfolio at GSK/Novartis. The portfolio spanned solid tumors, hematology and supportive care as well as early stage development products. While at GSK, she has also led global and US marketing teams including new product launches.
Her broad-based experience includes pharmaceutical management and a variety of roles in clinical development and medical affairs at Johnson and Johnson.
Girish Gangadharan has been in Corporate Strategy and Development at Analogic Corporation since 2011. He has been leading teams in corporate M&A, business development and strategic partnerships within Analogic for the last two years.
Prior to joining Analogic, Girish was a senior consultant in India where he specialized in business strategy, financial diligence and startup valuations for several years.
With a strong knowledge of business strategy, accounting and auditing practices, and financial valuations, Girish has been responsible for leading global expansion and development strategies through M&A and strategic investments.
Girish is also responsible for leading strategic planning for Analogic business units ranging from around $150 to $300 million in annual revenues.
Girish holds a Master of Science degree and a Master of Business Administration degree from Boston University.
Bob Haesemeyer is Director, New Product Planning at Purdue Pharma L.P. since March 2017 where he is focused on supporting the company’s pipeline diversification efforts. Bob has worked in various in-line, Global Marketing, and New Product Planning roles over the last 26 years with companies including Johnson & Johnson, Bristol-Myers Squibb, and Pfizer. He has a breadth of experience working in multiple therapeutic areas, in both primary care and specialist settings, and with small molecules and biologics.
Damon Harrell is currently responsible for the global planning and comprehensive assessment of the commercial capabilities required to succeed with post proof-of-concept molecules in the therapeutic areas of Major Depressive Disorders, Pain, Multiple Sclerosis, Alzheimer’s and Oncology. Mr. Harrell’s areas of focus include lifecycle management and facilitating cross-functional working to ensure that prescriber, patient, and payer perspectives are integrated into development plans. His experiences over the last 20 years include multiple therapeutic areas (dermatology, urology, antibiotics, pain, respiratory, anesthesia, cardiovascular, neurology, oncology, and depression) and business disciplines including: sales, promotion, market research, managed care, outcomes research, access, marketing and strategy for US, UK, EU and global territories. Mr. Harrell’s product launch experiences include SINGULAIR (adult and pediatric), FOSAMAX once weekly, and TREDAPTIVE.
Trained as medical doctor, innovation consultant and executive coach, Kasia Hein-Peters, MD has more than 20 years of experience in pharmaceutical industry, in both developed and emerging markets. She specializes in launching new medicines and vaccines, managing product life-cycle, and developing integrated stakeholder engagement campaigns. Through mentoring and coaching, Kasia builds highly performing, diverse teams. She likes speaking on global brand management, multicultural marketing and human-centric approach in pharma marketing. Currently, Kasia is preparing launch of a new hexavalent vaccine as a Marketing Head of MCM Vaccine, a joint-venture between Sanofi Pasteur and Merck & Co., Inc./MSD.
Lisa is the Global Pipeline Commercial Leader for the specialty franchise at GSK. This group covers a diverse set of therapeutic areas including Immune-Inflammatory, Oncology, Metabolic, and Neuroscience. All of the commercial aspects of the assets, within these diverse TAs, are managed by the pipeline commercial team, until they pass through the P2 Stage-gate. Currently, Lisa spends the majority of her time providing commercial leadership for GSK’916, a BCMA-ADC for Multiple Myeloma, which has recently received BTD from the FDA.
Lisa is an internist by training and started her career in clinical development. She moved into marketing over 15 years ago and has had a variety of in-line, above country and international LOC marketing roles. Lisa has also marketed primary care, specialty, and vaccines products across the life cycle, from early asset to branded generics.
Outside of work, Lisa spends her time writing, attempting to train her headstrong dogs, and providing love and advice to her two amazing daughters who are making their way in the world.
Ira Klein, M.D., MBA, FACP, is the Senior Director of Health Care Quality Strategy in the Strategic Customer Group of J&J Health Care Services, advancing value-based solutions for market access. He previously spent 10 years at Aetna, was the National Medical Director for Clinical Thought Leadership, founded the Oncology Solutions team, and held a variety of other roles.
Prior to Aetna, he led the quality, cost and care management area for the Bayshore Community Health System. Previous to that, he was CMO of Elderplan, serving the frail elderly in NYC. He began his career practicing internal medicine for seven years at Robert Wood Johnson Medical School as Assistant Professor in the Division of General Internal Medicine.
Ira holds a B.S. from Rutgers University College of Pharmacy, an M.D. from University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School, and an MBA from Rutgers University.
Dr. Ann Miller is an experienced Biopharma business executive with clinical training and extensive experience developing and executing launch and growth strategies across a wide range of specialty and primary care portfolios and products. She is an experienced Global and U.S. commercial leader who is effective in creating cross-functional collaborations and integrating strategies across commercial, market access/HEOR, Medical Affairs, R&D, and regions. Throughout her career, she has been recognized for her expertise in strategic marketing and the development of life cycle management strategies. Currently, Dr. Miller is VP, Marketing at Sanofi. She joined Sanofi in 2012 as the VP, Global Marketing, Oncology with responsibility across pipeline, launch and in-market products. Dr. Miller started her career at Merck in a Medical Affairs role but quickly moved into brand management, where she advanced through multiple business roles to lead the U.S. Osteoporosis franchise. In 2002, she moved to Amgen as the Global Marketing Therapeutic Area Head for Oncology, during which time she actively participated in building the Global Marketing function, with a focus on product strategy development across the life-cycle, as part of Amgen’s transformation to being a global company; following that role, she led the US pre-launch activities for Prolia, Amgen’s innovative osteoporosis product. After leaving Amgen to return to the east coast, Dr. Miller spent several years at Eisai where her roles included Senior VP, Primary Care and Specialty Business Unit, with Sales, Marketing and Medical Affairs responsibilities for the $3B business unit. Dr. Miller is a graduate of Duke Medical School and trained in Internal Medicine at the Hospital of the University of Pennsylvania. She also received her undergraduate degree in Chemistry from Duke University.
Over 10 years at Biogen, Liam Moy has held a variety of positions in US Therapeutic Operations including responsibilities with commercial operations, finance, market research, inventory management, REMS reporting, and business analysis.
Liam is currently responsible for managing commercial services launches for all new products launched by Biogen. This has included multiple products for both Hemophilia and Multiple Sclerosis as well as Spinraza for Spinal Muscular Atrophy product. Currently, Liam is on the team creating the launch strategy for Biogen’s Alzheimer’s products.
Brad Payne is a Vice President for Artisan Healthcare Consulting, and advises clients on how to optimize commercial outcomes for their own pipeline and newly launched products. He has lead and delivered >100 consulting engagements with established and emerging pharmaceutical, biotech, and medical device companies, and across therapeutic areas such as oncology, rare diseases, cardiovascular, and vaccines.
Brad’s expertise includes:
Prior to joining Artisan, Brad worked as a consultant at Trinity Partners. He holds a BA (cum laude) in Economics from Harvard University and an MBA from Arizona State University.
Tony Russell is currently the Senior Director, Product Strategy and Commercial Planning on Theravance Biopharma with a primary focus on new product planning for respiratory and dermatology. Tony’s prior therapeutic area experiences include pain, oncology, rare diseases, anemia, and nephrology.
Over the course of Tony’s nearly 20-year career, he has established a unique blend of skills and therapeutic area knowledge providing valuable perspectives and insights for the development and commercialization of biologic and small molecule therapeutics. Tony has successfully utilized these experiences in developing commercialization strategies and evaluations for new drug candidates as well as in the market conditioning and launching of new therapeutics.
Kristin Squires is Senior Marketing Director, Acne Franchise at Sun Pharmaceutical, where she leads the brand management and healthcare professional/patient/caregiver promotional strategy for two brands. Prior to Sun Pharmaceutical, Kristin was with Endo Pharmaceuticals for 10 years in various marketing roles across several therapeutic areas.
She also has experience from sanofi-aventis and several health care communications agencies including public relations, patient education and medical education. Throughout her career, she has led multiple product launches and execution of lifecycle management strategies.
She received her MBA from LaSalle University and BA from The College of New Jersey.
David Staknis is a Principal and Global Lead of Fuld + Company’s Health + Life Sciences Practice and has been with the practice for a decade. In his tenure, he has supported pharma, biotech, diagnostic, medical devices and service providers in a variety of strategic and tactical needs. These needs ranged from business development acquisition targets, early-stage R&D, late-stage clinical development and commercialization strategies and tactics.
Prior to joining Fuld + Company, David was a Senior Analyst and Division Leader at Global Prior Art, Inc., an intellectual property search and consulting firm. In that position, he worked closely with law firms, biotechnology, and pharmaceutical companies to support patent litigation, freedom-to-operate analyses, and intellectual property landscape creation
David holds a B.S. in biology from Syracuse University and a Ph.D. in cellular and developmental biology from Harvard University. He also was a biology instructor at Northeastern University.
Katja Wachtendonk is a Global New Products Director at Novartis Pharma. In her role, Katja is responsible to establish Novartis Global Cardio-renal & Metabolic Disease Area- and Program Strategies for compounds in Ph-I to early Ph-III in close collaboration with R&D. Katja leads and aligns portfolio strategies to maximize the value of assets and execute against short- and long-range franchise goals, provides commercial expertise to support BD&L, identifies transformational strategies (biomarker, diagnostics, etc) and innovates by leveraging technology-enabled solutions to improve patient outcomes.
Prior to that role, Katja spent more than a decade in global and local marketing leadership roles on Merck and Novartis blockbuster products SINGULAIR, COZAAR, ULTIBRO, QVM149, QAW039 from early Ph-III through launch and LoE in the U.S., Germany and Japan, and supported the companies’ business in Europe, AMAC and LACAN.
Katja holds a Pharm.D. from the Freie Universitaet Berlin (Germany).